Ergomed - Trading update reflects powerful growth and strong execution

Davy Research
/Read Important Disclosures

Ergomed has released a trading update announcing strong revenue growth in 2022 of 23% plus similar growth in its order book, providing visibility on 2023. The business continues to execute well with 2022 EBITDA in line with forecasts. The balance sheet is net cash, providing optionality on acquisition growth.